FYI: GLP-1s are quietly rewriting romance and work in America. Here's the facts.

Cool.

Today we're going to talk about the two places where GLP-1s are actually reshaping American life, and most of the coverage is either missing it or scared to name it: the bedroom and the boardroom.

Both stories share the same mechanism. And both stories are bigger than anyone is saying out loud.

This is Off Label, Not Medical Advice.

Let's go.

The Morning Read: GLP-1s are quietly rewriting American romance and the American workplace. The data is wild.

Here is what researchers, HR leaders, and marriage therapists are actually measuring right now.

Those four numbers are from four separate, credible sources published in the last twelve months. They tell a story that mainstream GLP-1 coverage has barely named.

Let's unpack it.

Before we go into romance and work, one thing you need to know about how GLP-1s actually work in the brain. It explains everything downstream.

Semaglutide and tirzepatide don't just suppress appetite. They lower dopamine activity in your brain's reward and attachment circuits. A 2024 study (Lengsfeld et al.) documented this directly. The Kinsey Institute's March 2026 review in Obesity Pillars confirmed it.

Dopamine is what drives cravings for food, for alcohol, for sex, for romantic obsession, for the rush you get from a win at work. GLP-1s dampen that signal across the board.

That's why users report:

One mechanism. Many downstream changes. The reason this matters: if you or your partner is on a GLP-1 and feels emotionally different, it's not imagined. The drug is literally affecting the circuits that produce those feelings.

Now, the two places this is showing up hardest.

The Kinsey Institute (arguably the most respected sex research institution in America) partnered with DatingAdvice.com in 2025 to survey GLP-1 users. ZipHealth surveyed another 1,000 single Americans in March 2026. The New York Times Daily podcast did a full episode called "Marriage and Sex in the Age of Ozempic" last October.

The data across sources:

Here's the part almost nobody is talking about.

43% of single GLP-1 users have NOT disclosed their medication use to anyone they're dating.

Nearly half of single users are carrying the drug as a secret into new relationships. The disclosure question (when and how to tell a partner) has become the new defining challenge in modern dating, the way STD disclosure and income disclosure evolved before it.

If you're dating someone who recently lost significant weight and has different food, drinking, or energy patterns, there is a nearly fifty-fifty chance they're on a GLP-1 and haven't told you.

The marriage side is where the data gets hard.

In early 2026, researchers from Sweden's Institute of Health and Care Sciences published a cohort study of approximately 12,500 patients who underwent rapid weight loss.

14% of those patients divorced within six years. The general population baseline is 8%.

Nearly double.

This builds on earlier University of Pittsburgh research from 2022 (Wendy King) showing US bariatric surgery patients were 2.2 times more likely to divorce within 5 years than the general population. The lead Swedish researcher, Professor Per-Arne Svensson, has explicitly stated that similar mechanisms are likely happening with GLP-1 receptor agonists.

The phrase "bariatric divorce" has been in clinical literature for years. It's now being applied, quietly, to GLP-1 outcomes.

Here's the part to internalize. The divorce risk isn't evenly distributed. The pattern researchers see is:

The asymmetry is the problem, not the drug itself. The medicated partner experiences an identity shift (new body, new appetite, new social dynamics, new energy, sometimes new attachment patterns). The non-medicated partner is still living in the relationship that existed before the drug.

Psychology Today called it a "drastic schism" in the couple's experiences of self. Christine Walter Coaching called it "mourning what is changing rather than pretending it isn't." The clinical consensus is forming: GLP-1 partners who talk openly about what's shifting do better than partners who don't.

The workplace is the other place GLP-1s are rewriting the rules. Most of this is happening silently, inside HR meetings and benefits renewal conversations you'll never see.

The current landscape:

Here are the three workplace numbers that should move any HR leader reading this:

Translation: cutting GLP-1 coverage to save money often costs more money than keeping it. The math has flipped.

Three things readers should know as they navigate this themselves.

There's no mandate that you tell a date you're on a GLP-1. But clinicians and therapists are increasingly asking their patients to think about when disclosure happens, because relationship outcomes are measurably better when it does. Earlier disclosure is not always right. But silent, indefinite non-disclosure correlates with relationship instability.

The dopamine effect is real. If you feel like you're going through the motions, less attached, less obsessed with things you used to love, that is a documented effect of the drug on brain chemistry. It's worth naming with your doctor and your partner. It doesn't mean you're broken. It means the drug is working on more circuits than food.

If you're interviewing or in a salary negotiation, GLP-1 coverage is a legitimate ask alongside remote work, vacation days, and 401k matching. Companies increasingly expect the question. The "do you cover GLP-1s" question during interviews isn't weird anymore. It's informed.

Text your doctor this: "Since starting my GLP-1, I've noticed changes in my mood, emotional attachment, and libido that feel bigger than just weight loss. I've read GLP-1s can affect dopamine and reward pathways. Can we talk about whether this is expected, whether it might stabilize, and whether there are adjustments to consider?"

This is the conversation worth having. Specific, informed, opens the door without demanding a prescription change.

The classic dinner-and-drinks date is quietly dying. GLP-1 users don't want a three-hour meal paired with wine they can't finish. Walking dates, coffee dates, morning dates, activity dates are rising. This is already starting to affect restaurant and bar revenue in high-GLP-1 demographic markets.

Dating apps are debating whether GLP-1 disclosure should be a profile option. Conversations inside Match Group (Hinge, Tinder, OKCupid), Bumble, and Grindr are surfacing. No app has launched a feature yet. Whichever moves first sets the norm.

"Bariatric divorce" has entered the popular vocabulary. What was clinical jargon is now being used casually in Substacks, podcasts, and online discourse. Expect a wave of articles, books, and TikTok therapists over the next 12 months.

Employer coverage has become a talent war signal. Companies that cover GLP-1s are quietly winning retention battles in the 35 to 64 demographic. This is especially intense in industries where healthcare costs are already the biggest operating expense after salaries.

The Kinsey Institute has officially entered the GLP-1 research space. When arguably the most respected sex research institution in America formalizes a research line on a drug class, that class has crossed into cultural permanence. GLP-1s are now a variable in mainstream social science, not just pharma.

Watch this: Match Group (MTCH). Match owns Hinge, Tinder, OKCupid, Match.com, and a dozen other dating apps. Internal conversations in the industry are debating whether GLP-1 disclosure should become a profile option. No app has launched it yet, but whichever one moves first establishes a new norm in the dating space. The market reaction to an early GLP-1 feature launch will signal whether the industry views this as risk or trend. Also worth tracking: Bumble (BMBL) and Grindr (GRND) product updates that reference health or wellness disclosure in Q2 or Q3 2026.

Tomorrow: the mailbag. We're opening up reader questions from the first week of Off Label. The single question we've gotten more than any other. The surprise favorite. And the one that required a whole research dive to answer properly.

Hit reply and tell us what you want us to cover. Every reply is read. Story tips: [email protected]

See you in your inbox.

— Off Label

This is Off Label, Not Medical Advice. Content is for informational purposes only. Always consult a qualified healthcare provider before making medical decisions. This applies especially to concerns about emotional changes, libido shifts, or relationship dynamics you believe may be related to medication use.